ALX Oncology Holdings Inc. (ALXO) Q2 2025 Earnings Call Transcript

ALX Oncology Holdings Inc. (NASDAQ:ALXO) Q2 2025 Earnings Conference Call August 12, 2023 4:30 AM ET

Company Participants

Alan Bart Sandler – Chief Medical Officer
Harish Shantharam – Chief Financial Officer
Jason W. Lettmann – CEO & Director

Conference Call Participants

Allison Marie Bratzel – Piper Sandler & Co., Research Division
Li Wang Watsek – Cantor Fitzgerald & Co., Research Division
Roger Song – Jefferies LLC, Research Division
Samuel Evan Slutsky – LifeSci Capital, LLC, Research Division
Ting Liu – UBS Investment Bank, Research Division
Yu He – H.C. Wainwright & Co, LLC, Research Division

Jason W. Lettmann

Thanks, everyone, and welcome to our Q2 2025 results. I appreciate everybody spending some time this afternoon with us and looking forward to this update. On Slide 2, before we start our presentation, as housekeeping, here are our forward-looking statements for your review.

So, in terms of Slide 3, this is the agenda and plan for today. We’re going to be providing an update on our key accomplishments in the second quarter of 2025. Most notably, we are very excited to share with you new data from our analysis of ASPEN — our ASPEN-06 trial that showed CD47 expression as a key predictive biomarker for increasing clinical response with evorpacept.

So our goals for today are, most importantly, to share this new data with you all, then give you a sense of how this data now impacts our development strategy for Evo, then provide a quick update on our novel EGFR-targeted ADC, ALX2004, which is set to enter the clinic imminently as well as share revised guidance on our financials and cash position.

Som in terms of the agenda, our CMO, Alan, will first present these top line results and also provide an update of our clinical programs with Evo. Harish will then conclude by an